Also known as: MT-2; related: afamelanotide (Scenesse)
A tanning peptide sold online. Its cousin afamelanotide is approved for a rare light-sensitivity disease.
Educational reference, not medical advice. Many compounds here are not approved, and products sold as research chemicals are not checked for purity. Plan any use with a licensed clinician.
How it works
Activates melanocortin receptors (MC1R for pigment, MC4R for libido and appetite).
Evidence by goal
| Goal | Grade | What the grade means |
|---|---|---|
| Skin, hair & appearance | C | Limited human data, case series or practitioner reports |
| Libido & sexual function | C | Limited human data, case series or practitioner reports |
At a glance
- Route
- Subcutaneous or nasal
- Half-life
- About 1 hour
Reported dosing
Loading: 0.25 to 0.5 mg daily until desired color. Maintenance: 0.5 mg 1 to 2 times weekly (user reports).
Timing: Evening, to sleep through nausea.
Cycle: Loading 1 to 3 weeks, then maintenance.
From approved labels where they exist, otherwise from published trials and practitioner reports.
Side effects
- Nausea, flushing, yawning
- Spontaneous erections
- New or darkening moles
Who should avoid it
- Personal or family history of melanoma
- Many atypical moles
- High blood pressure
Often combined with
Do not combine with PT-141.
Key findings
Case reports link it to changing moles and melanoma. Afamelanotide (16 mg implant every 2 months) is approved for erythropoietic protoporphyria.
Where it is legal (Oct 2026)
| US | Not approved |
|---|---|
| Canada | Not approved |
| Mexico | Not approved |
| EU | Not approved |
Health Canada, US, UK and Australian regulators have issued public warnings.
Sources
Open Melanotan II in the Peptide Guide Compare all peptides by goal
Last reviewed November 2026. Regulatory status reflects the US unless noted and changes often.